EGFR and leukemia: Considerable evidence suggests that induction of cytotoxic activity and differentiation occurs with other inhibitors of EGFR, such as gefitinib and erlotinib, in both leukemia cell lines and leukemia patients [37], [38], [39], [40], [41], [42], [43], [44], [45].